NCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT07043608 2025-07-02
ZAMBONI
University of California, San Francisco
Phase 2 Not yet recruiting
NCT03280667 2023-03-29
KEYPAD
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT03520231 2021-11-23
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
University Health Network, Toronto
Phase 2 Completed
NCT03408652 2021-10-22
MOSCAR
Centre Leon Berard
Phase 3 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated